Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCB-808
- Development stage
- Unknown
- Lead developer
- Clover Biopharmaceuticals
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
SCB-808 is a biosimilar candidate to Enbrel (etanercept), a recombinant fusion protein consisting of the extracellular ligand-binding portion of the human tumor necrosis factor receptor 2 linked to the Fc portion of human immunoglobulin G1. **It acts as a tumor necrosis factor (TNF) inhibitor**, neutralizing TNF-alpha and TNF-beta to reduce inflammation in autoimmune diseases. Developed by **Clover Biopharmaceuticals**, SCB-808 is formulated as a prefilled syringe for convenient subcutaneous self-administration, distinguishing it from powder formulations of other Chinese etanercept biosimilars. It has advanced through Phase 1 pharmacokinetic studies and into Phase 3 trials in China for rheumatic diseases, with preclinical comparisons showing similarity to Enbrel.[1][2][4][10]
- Other names
- etanercept biosimilar
02
Targets
LTA (Lymphotoxin-alpha)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on SCB-808.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCB-808.